Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q3 2022 · 10-Q
Revenue$680.80M$680.80M−8.9% vs Q3 2021 Net Income-$162.80M-$162.80MN/M vs Q3 2021 EPS Diluted-$5.48-$5.48N/M vs Q3 2021 Gross Profit$372,600,000−14.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
Operating Cash Flowderived$11,027,000−95.2% Free Cash Flowderived-$16,548,000N/M Margins · derivedGross margin54.7%−3.7 pt vs Q3 2021
Operating margin13.9%−7.1 pt vs Q3 2021
Net margin-23.9%
ended Sep 30, 2022 · filed Oct 28, 2022 · 28 d after period end